Sign in

    Hayman Chiu

    Research Director and Senior Equity Analyst at Haitong International Securities

    Hayman Chiu is a Research Director and Senior Equity Analyst at Cinda International, previously associated with Haitong International Securities, specializing in Hong Kong-listed equities with a focus on sectors including healthcare, industrials, and consumer companies. He has provided coverage for companies such as Universal Medical, Hokai Medical Instruments, Concord Medical Services, and Xtep, delivering investment research to institutional clients and helping them understand critical market movements and trends. Chiu began his analyst career prior to 2016 and has played a leadership role in research teams, with his analyses referenced across investor relations materials for numerous Hong Kong-listed firms. While specific performance metrics and professional credentials such as FINRA registration or securities licenses are not publicly available, he is recognized as an influential voice in Asian equity markets.

    Hayman Chiu's questions to PETROCHINA CO (PCCYF) leadership

    Hayman Chiu's questions to PETROCHINA CO (PCCYF) leadership • Q2 2022

    Question

    Hayman Chiu of Haitong International Securities inquired about the rationale behind PetroChina's delisting from the New York Stock Exchange and the company's progress and future plans for its green and low-carbon transition, including new energy and new materials projects.

    Answer

    CFO and Board Secretary Wang Hua explained that the NYSE delisting was driven by the ADRs' small trading volume and percentage of total shares, the high administrative burden of maintaining the listing, and the continued trading availability of H and A shares in Hong Kong and Shanghai. Chairman Dai Houliang detailed the company's three-step green transition strategy, noting that H1 2022 progress in wind, solar, and geothermal projects was ahead of schedule. He outlined a goal for new energies, oil, and gas to each constitute one-third of production capacity by 2035.

    Ask Fintool Equity Research AI